Polydactyly of an index finger

Summary

Polydactyly of an index finger (MONDO:0008271) is a disease. A subtype of preaxial polydactyly of fingers — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Europe)

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	<1 / 1 000 000		Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	polydactyly of an index finger
Mondo ID	MONDO:0008271
MeSH	C566784
OMIM	174600
Orphanet	93337
ICD-11	982050714
SNOMED CT	723446006
UMLS	C1868113
MedGen	357422
GARD	0002256
Is cancer (heuristic)	no

Also known as: polydactyly, preaxial type 3 · PPD3 · preaxial polydactyly type 3

Disease family

This is a subtype of preaxial polydactyly of fingers. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › polydactyly › non-syndromic polydactyly › preaxial polydactyly of fingers › polydactyly of an index finger

Related subtypes (2): polydactyly of a biphalangeal thumb, polydactyly of a triphalangeal thumb

Subtypes (2): polydactyly of an index finger, unilateral, polydactyly of an index finger, bilateral

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.